Levi & Korsinsky, LLP announces that a KRBP class action lawsuit has been filed on behalf of investors who purchased Kiromic BioPharma, Inc. (KRBP) This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Kiromic common stock issued in connection with the Company’s public offering that closed on July 2, 2021, and/or (b) Kiromic common stock between June 25, 2021, and August 13, 2021, both dates inclusive. For more on the KRBP Lawsuit please contact us today.
According to the Kiromic lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: The complaint alleges that the registration statement and prospectus issued in connection with the Company’s public offering that closed on July 2, 2021 (the “Offering Documents”) failed to disclose that the Food and Drug Administration (“FDA”) had, prior to the filing of these documents, imposed a clinical hold on the Company’s Investigational New Drug (“IND”) applications for its two new drug candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence.
If you suffered a loss in Kiromic you have until October 4, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171